Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
44 hedge funds and large institutions have $7.6M invested in Eiger BioPharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 51 closing their positions.
103% more call options, than puts
Call options by funds: $1.25M | Put options by funds: $614K
50% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 12
48% less funds holding
Funds holding: 84 → 44 (-40)
78% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 51
97% less capital invested
Capital invested by funds: $297M → $7.6M (-$290M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$17.5M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$1.62M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.01M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$969K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$913K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$44M |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$36.6M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$27.4M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$18.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$18.4M |
EIGR Hedge Fund Activity: Q2 2015 in Review
44 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q2 2015, worth a combined $7.6M — down 97% from $297M a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of EIGR and 11 opened new positions — a net loss of 40 holders — while 12 trimmed existing stakes and 18 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $17.5M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $44M sold.
- 44 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q2 2015, down from 84 in Q1 2015.
- Funds reported $7.6M of Eiger BioPharmaceuticals, Inc. stock for Q2 2015, down 97% quarter-over-quarter.
- 11 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q2 2015 and 51 closed out, a net change of -40 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q2 2015 was EcoR1 Capital, an estimated $17.5M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q2 2015 was Eagle Asset Management, an estimated $44M sold.
Based on aggregated 13F filings for Q2 2015.